Neurologic Imaging

Which Imaging Is Best for Suspected Recurrence in Treated Head and Neck Cancer?

·
Which Imaging Is Best for Suspected Recurrence in Treated Head and Neck Cancer?

It’s a busy afternoon in the otolaryngology clinic. You are seeing a 62-year-old patient for a six-month follow-up visit after he completed chemoradiation for HPV-positive oropharyngeal squamous cell carcinoma. He feels well but points to a subtle new fullness in his left neck, near the previously treated nodal disease. Physical exam is equivocal due to post-treatment firmness. You need to determine if this represents benign post-treatment change or recurrent cancer. This clinical workflow article details the American College of Radiology (ACR) guidance for this exact scenario: surveillance or follow-up imaging for suspected recurrence in treated cancers of the oral cavity, oropharynx, hypopharynx, or larynx. For this presentation, the ACR rates MRI of the orbits, face, and neck without and with IV contrast as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to patients with a history of treated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx, or a cancer of unknown primary in the head and neck. The key distinction is that the patient has already undergone definitive therapy—such as surgery, radiation, chemotherapy, or a combination—and is now being evaluated either for routine surveillance or due to new signs or symptoms concerning for recurrence. These symptoms can be subtle, including new pain, dysphagia, hoarseness, a new neck mass, or nonspecific fullness.

This workflow should not be applied to patients with different clinical histories, even if they seem similar. Key exclusions include:

  • Initial Staging: Patients with a new, biopsy-proven malignancy who have not yet received treatment require a different imaging workup for initial staging. This is a separate ACR scenario focused on defining the full extent of the primary tumor and nodal disease before therapy begins.
  • Nasopharyngeal or Sinus Cancers: Patients with treated nasopharyngeal carcinoma (often EBV-associated) or cancers of the paranasal sinuses or nasal cavity follow distinct surveillance protocols. These tumors have different patterns of spread and recurrence, particularly a higher risk of skull base invasion, which alters imaging priorities.
  • Salivary Gland Malignancies: Post-treatment surveillance for cancers of the parotid, submandibular, or other salivary glands also constitutes a separate clinical scenario with its own imaging considerations.

What Diagnoses Are You Working Up in This Scenario?

In the post-treatment setting, the differential diagnosis for new symptoms or imaging findings is narrow but critical. The primary goal of imaging is to distinguish between cancer recurrence and the expected after-effects of therapy.

Local or Regional Recurrence
This is the most consequential diagnosis and the primary target of surveillance imaging. Recurrence can occur at the original primary tumor site (local), in the regional lymph nodes of the neck (regional), or both. Distinguishing a small recurrent tumor from surrounding scar tissue is the central challenge for the radiologist and the reason specific imaging modalities are preferred.

Post-Treatment Changes
Therapy, particularly radiation, fundamentally alters the anatomy and tissue characteristics of the head and neck. The most common mimic of recurrence is post-treatment fibrosis, inflammation, and edema. These changes can create palpable firmness, soft tissue thickening, and enhancement on imaging that can be difficult to differentiate from a viable tumor. This is a benign, expected finding, but one that must be confidently excluded.

Second Primary Tumor
Patients with a history of head and neck squamous cell carcinoma, especially those with significant tobacco and alcohol exposure, are at a substantially increased risk of developing a new, second primary tumor elsewhere in the upper aerodigestive tract. Surveillance imaging may incidentally detect a new lesion in the oral cavity, pharynx, larynx, or esophagus that is unrelated to the originally treated cancer.

Radiation-Associated Complications
Less commonly, imaging may reveal complications from prior therapy, such as osteoradionecrosis of the mandible or hyoid bone, which can present with pain and swelling. While not a malignancy, identifying this is crucial for patient management.

Why Is MRI of the Orbits, Face, and Neck the Recommended Study?

For surveillance and evaluation of suspected recurrence in treated head and neck cancer, the ACR designates MRI of the orbits, face, and neck without and with IV contrast as a Usually Appropriate study. The rationale is grounded in MRI’s superior ability to characterize soft tissues, which is paramount in the complex post-treatment environment.

The primary advantage of MRI is its exceptional soft-tissue contrast resolution. It can often differentiate between post-radiation fibrosis, which typically appears as low-signal, non-enhancing scar tissue, and recurrent tumor, which is cellular and tends to enhance and show restricted diffusion on specific sequences like Diffusion-Weighted Imaging (DWI). This distinction is far more difficult to make with other modalities. Furthermore, MRI involves no ionizing radiation (0 mSv), a significant benefit for patients who may require multiple surveillance scans over many years.

Other modalities are also rated for this scenario, but with important caveats:

  • CT neck with IV contrast is also rated Usually Appropriate. It is faster to acquire than MRI and less susceptible to motion and dental hardware artifact. However, its inferior soft-tissue contrast makes it more challenging to distinguish scar from tumor. It remains a valuable alternative if MRI is contraindicated or unavailable. It involves a moderate radiation dose (☢☢☢ 1-10 mSv).
  • FDG-PET/CT skull base to mid-thigh is also Usually Appropriate. This modality provides functional information about metabolic activity rather than just anatomy. It is highly sensitive for detecting recurrent disease and is the best test for identifying distant metastases. However, it can be falsely positive due to post-treatment inflammation, especially if performed within three months of completing radiation therapy. It also carries the highest radiation dose of the recommended options (☢☢☢☢ 10-30 mSv) and is often reserved for problem-solving equivocal findings on MRI/CT or for patients at high risk of recurrence.
  • US neck is rated May be appropriate. Ultrasound is excellent for evaluating superficial cervical lymph nodes and can guide fine-needle aspiration. However, it cannot visualize the primary tumor site in the pharynx or larynx or deep neck spaces, making it an incomplete surveillance tool on its own.

What’s Next After MRI? Downstream Workflow

The results of the surveillance MRI will guide the subsequent clinical pathway. The goal is to achieve a definitive diagnosis that can be presented to a multidisciplinary tumor board for consensus treatment recommendations.

If the MRI is clearly positive for recurrence:
A report indicating high suspicion for recurrent tumor, either at the primary site or in regional nodes, should prompt an urgent referral back to the head and neck surgical and radiation oncology teams. The next step is almost always a biopsy to obtain pathologic confirmation. This may be an image-guided fine-needle aspiration (FNA) for a suspicious lymph node or a direct endoscopic biopsy for a mucosal lesion. Once confirmed, the tumor board will determine the best course for salvage therapy.

If the MRI is negative:
A definitively negative scan showing only expected post-treatment changes and no suspicious findings is reassuring. The patient can typically return to their standard clinical follow-up schedule, which often includes regular physical exams and direct endoscopic visualization of the treated area.

If the MRI is indeterminate or equivocal:
This is a very common outcome. Post-treatment anatomy can be complex, and a finding may be ambiguous. In this situation, the workflow branches:

  1. Problem-Solving with PET/CT: If not already performed, obtaining an FDG-PET/CT is often the best next step. A metabolically “cold” or inactive area is very unlikely to be a recurrent tumor, whereas a “hot” or hypermetabolic focus increases suspicion and can guide a biopsy.
  2. Short-Interval Follow-up Imaging: If suspicion is low, a short-interval follow-up MRI in 6-12 weeks can be performed to assess for stability or progression. A stable finding is likely benign post-treatment change.
  3. Examination Under Anesthesia: For accessible sites, an examination under anesthesia with direct visualization and biopsies of any suspicious areas may be the most direct path to a diagnosis.

Pitfalls to Avoid (and When to Get Help)

Navigating post-treatment surveillance requires careful attention to timing and technique to avoid misinterpretation.

  • Pitfall 1: Imaging Too Soon After Therapy. Performing FDG-PET/CT less than 12 weeks after the completion of radiation therapy can lead to high rates of false-positive results due to lingering inflammation. A baseline post-treatment scan is typically performed around the 3-month mark.
  • Pitfall 2: Underestimating Post-Treatment Changes. Normal fibrosis, edema, and mucosal enhancement can persist for months to years after treatment. Always ensure the interpreting radiologist has access to prior imaging studies, including the pre-treatment scan, to establish a baseline and accurately assess for change.
  • Pitfall 3: Ordering the Wrong Protocol. A generic “MRI Neck” may not include the specific sequences (like fat-suppressed post-contrast images and DWI) or the appropriate field of view (from the skull base through the thoracic inlet) needed for a comprehensive cancer surveillance study. Be specific in your order.

If an imaging study is equivocal and the next step is unclear, the best course of action is to present the case at a multidisciplinary head and neck tumor board. The collective input from radiology, surgery, radiation oncology, and medical oncology is invaluable for resolving diagnostic uncertainty.

Related ACR Topics and Tools

This article covers a single, specific clinical scenario. For a comprehensive overview of all variants and initial staging protocols, or to explore the technical details of the recommended imaging studies, the following resources are essential.

Frequently Asked Questions

Why is MRI generally preferred over CT for surveillance of treated oropharyngeal cancer?

MRI is preferred due to its superior soft-tissue contrast resolution. This allows it to better differentiate between benign post-treatment changes, like fibrosis and scarring, and recurrent tumor. Key MRI sequences like Diffusion-Weighted Imaging (DWI) can also assess tissue cellularity, further helping to distinguish cancer from scar. While CT is a valid alternative, this distinction is often more difficult.

How soon after treatment should the first surveillance scan be performed?

The timing of the first post-treatment scan is critical and often guided by institutional protocols and patient risk factors. A common approach is to obtain a baseline scan, often an FDG-PET/CT, approximately 3 months after the completion of radiation therapy. This delay is crucial to allow post-treatment inflammation to subside, reducing the risk of a false-positive result.

What is the specific role of FDG-PET/CT in this surveillance scenario?

According to the ACR, FDG-PET/CT is ‘Usually Appropriate.’ Its primary roles are as a baseline study about 3 months post-treatment, as a problem-solving tool for equivocal findings on MRI or CT, and for detecting distant metastatic disease. It assesses the metabolic activity of tissue, which can help confirm or refute suspicion of recurrence seen on anatomic imaging.

Is ultrasound useful for follow-up after head and neck cancer treatment?

Ultrasound is rated as ‘May be appropriate.’ It is a valuable tool for examining superficial structures, particularly the cervical lymph nodes, and can be used to guide fine-needle aspiration biopsies of suspicious nodes. However, it cannot visualize deeper structures like the primary tumor site in the oropharynx or larynx, so it is not sufficient as a standalone surveillance modality for the entire treated area.

What if my patient has significant dental hardware that could degrade an MRI scan?

This is an important practical consideration. Significant metallic artifact from dental implants or prior surgical hardware can severely degrade MRI quality. In such cases, a contrast-enhanced CT of the neck is often the better choice. Alternatively, specialized MRI sequences designed to reduce metal artifact (known as MARS) can be employed if available, but CT may still provide a more diagnostic study.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026